J.P. Morgan Roundtable: Biotech Executives Expect Capital To Flow Despite Lower Valuations
This article was originally published in Scrip
Informa Pharma's Global Director of Content Mike Ward and Scrip Intelligence West Coast Editor Mandy Jackson moderated a roundtable discussion on Jan. 11, the opening day of the 34th Annual J.P. Morgan Healthcare Conference, in San Francisco during which they spoke with eight biotechnology veterans about the state of biotech going into 2016.
You may also be interested in...
The market for public offerings by biopharma companies is tough, but Corbus Pharmaceuticals, Loxo Oncology and Novavax used three different strategies to raise cash from new and existing shareholders.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.